Boston Scientific Corporation (BSX)
NYSE · Marlborough, Massachusetts, USA · Founded 1979 · CEO Michael Mahoney
Valuation summary
$41.43 fair value versus $42.99 in the market, a difference of -3.6%. Rated Hold.
| Fair value per share | $41.43 |
| Current share price | $42.99 |
| Upside / downside | -3.6% |
| Bear case | $22.96 |
| Bull case | $69.04 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 2.70% |
| Market capitalisation | $62B |
| EV / Sales | 3.5x |
About Boston Scientific Corporation
Founded in 1979 by John Abele and Peter Nicholas to commercialise less-invasive medical devices. Michael Mahoney has been CEO since 2012 and has overseen one of the strongest turnarounds in the sector. Boston Scientific makes cardiovascular devices, endoscopy equipment and urology products. Its Farapulse pulsed field ablation system, used to treat atrial fibrillation, has been the fastest device launch in the company's history.
Investment case
- Farapulse remains a leading pulsed field ablation system, and international electrophysiology sales grew 23% in the second quarter of 2026.
- A restructuring programme targeting roughly $500 million of run-rate savings gives management a lever on margins while growth slows.
- Well-executed acquisition strategy that has repeatedly bought growth at reasonable prices.
Key risks
- Medtronic, Johnson & Johnson and Abbott are taking US pulsed field ablation share, and US electrophysiology sales grew only 3% in the second quarter of 2026.
- Watchman demand has slowed sharply, with US stand-alone procedures down in the low teens in the second quarter of 2026 after new stroke-risk evidence reduced referrals.
- An August 2026 cyberattack cut third-quarter growth by about 3 points and EPS by $0.07, and management expects 2027 sales and EPS to be hard to grow.
Recent developments
- 2026-10-28 · Q3 organic growth slows to 1.5% after an eight-day cyber incident and share losses in EP and WATCHMAN; Q4 organic sales guided down 1% to 3% source
- 2026-10-28 · Management warns it will be challenged to grow sales and adjusted EPS in 2027 and expects a return to growth in 2028 source
- 2026-10-08 · Barclays upgraded the shares to hold after they hit a 52-week low near $41.50; CEO Michael Mahoney bought about $9 million of stock. source
- 2026-09-17 · Shares down about 54% since late December 2025 on US electrophysiology share loss and a Watchman slowdown; US EP sales grew 3% in Q2 vs 23% internationally. source
Revenue by segment
| Cardiovascular | 63% |
| MedSurg | 37% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $22.9B | $2.6B |
| Year 2 | $24.9B | $3.0B |
| Year 3 | $27.1B | $3.3B |
| Year 4 | $29.6B | $3.7B |
| Year 5 | $32.2B | $4.2B |
What the street says
Sentiment has reversed sharply: the shares lost more than half their value between late December 2025 and September 2026 as US electrophysiology share losses and a Watchman slowdown forced repeated guidance cuts. The third quarter of 2026 confirmed the damage, with organic growth of 1.5%, fourth-quarter organic sales guided down 1-3% and management warning it will be challenged to grow sales and EPS in 2027 before a return to growth in 2028.
Comparable companies: IQV · GEHC · MDLN · MDT · SYK · SNY · A · TEVA
Open the interactive model, price chart and sensitivity grid →